Cannabis and safety
Browse the latest research linking medical marijuana / medicinal cannabis and safety.
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
CBD safety in mice via experiment Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice May 2019
Our results demonstrate that prolonged CBD treatment has no negative effect on the behavior of adult C57Bl/6J mice.
Limonene safety in humans D-Limonene: safety and clinical applications. Sept 2007
Subsequent studies have determined how these tumors occur and established that d-limonene does not pose a mutagenic, carcinogenic, or nephrotoxic risk to humans. In humans, d-limonene has demonstrated low toxicity after single and repeated dosing for up to one year.
Sativex safety in humans via placebo trial (n=17) Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Jan 2009
Cannabinoid treatment did not induce psychopathology and did not impair cognition in cannabis-naive patients with MS.
cannabis safety in humans via trial (n=415) Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). Dec 2015
Ingestion Method: 12.5% THC cannabis
Positive  This study evaluated the safety of cannabis use by patients with chronic pain over 1 year. The study found that there was a higher rate of adverse events among cannabis users compared with controls but not for serious adverse events at an average dose of 2.5 g herbal cannabis per day.
Rimonabant safety via review An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. Feb 2011
Negative  Rimonabant is effective in reducing weight in the obese but may lead to intolerable adverse effects most notably psychiatric effects, which make it unsuitable for routine use. However, the drug provides useful proof of principle for this approach to weight loss.
Rimonabant safety via review Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Nov 2007
Negative  Our findings suggest that 20 mg per day rimonabant increases the risk of psychiatric adverse events--ie, depressed mood disorders and anxiety-despite depressed mood being an exclusion criterion in these trials. Taken together with the recent US Food and Drug Administration finding of increased risk of suicide during treatment with rimonabant, we recommend increased alertness by physicians to these potentially severe psychiatric adverse reactions.
Rimonabant safety via review Rimonabant: From RIO to Ban Jul 2011
The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome. However, the drug was quickly withdrawn due to the emergence of significant side effects--notably severe mood disorders
CBD metabolism,safety via review Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy Mar 2016
The present overview summarizes our current knowledge on the pharmacokinetics and metabolic fate of CBD in humans, reviews studies on the biological activity of CBD metabolites either in vitro or in vivo, and discusses relevant drug-drug interactions. To facilitate further research in the area, the reported syntheses of CBD metabolites are also catalogued.
CBD safety via review An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies Jun 2017
Neutral  This review also illustrates that some important toxicological parameters are yet to be studied, for example, if CBD has an effect on hormones. Additionally, more clinical trials with a greater number of participants and longer chronic CBD administration are still lacking.
CBD safety in mice via experiment Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model. Apr 2019
Ingestion Method: 0, 246, 738, or 2460 mg/kg
Negative  In conclusion, CBD exhibited clear signs of hepatotoxicity, possibly of a cholestatic nature. The involvement of numerous pathways associated with lipid and xenobiotic metabolism raises serious concerns about potential drug interactions as well as the safety of CBD.